Phase 2, Randomized, Dose-Ranging Study Evaluating the Safety and Efficacy of Anidulafungin in Invasive Candidiasis and Candidemia

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2004-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1128/AAC.48.6.2021-2024.2004PMID 15155194PMCID PMC415613
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

  2003cited by this paper
• A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

  2003cited by this paper
• A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

  2003cited by this paper
• Attributable mortality of nosocomial candidemia, revisited.

  2003cited by this paper
• Comparison of caspofungin and amphotericin B for invasive candidiasis.

  2002cited by this paper
• Echinocandins--an advance in the primary treatment of invasive candidiasis.

  2002cited by this paper
• Changing spectrum of invasive candidiasis and its therapeutic implications.

  2001cited by this paper
• Mortality and costs of acute renal failure associated with amphotericin B therapy.

  2001influential reference
• Coagulase-negative staphylococci as a cause of infections related to intravascular prosthetic devices: limitations of present therapy.

  2001cited by this paper
• International Surveillance of Bloodstream Infections Due toCandida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program

  2001cited by this paper
• Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.

  2000cited by this paper
• The epidemiology of candidemia in two United States cities: results of a population-based active surveillance.

  1999influential reference
• Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

  1999influential reference
• National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units.

  1999cited by this paper
• In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi.

  1998cited by this paper
• Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature.

  1996cited by this paper
• Epidemiological shifts in opportunistic and nosocomial Candida infections: mycological aspects.

  1996cited by this paper
• Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study.

  1996cited by this paper
• Epidemiology of nosocomial fungal infections

  1996cited by this paper
• Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study.

  1995cited by this paper
• A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

  1994cited by this paper
• A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia

  1994cited by this paper

• Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review

  2023cites this paper
• Molecular Mechanisms of Antifungal Resistance in Mucormycosis

  2022cites this paper
• Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents

  2022cites this paper
• Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?

  2022cites this paper
• Comparative efficacy and safety of systemic antifungal agents for candidemia: A systematic review with network meta-analysis and multicriteria acceptability analyses.

  2022cites this paper
• Echinocandins

  2021cites this paper
• Immunotherapy and Antifungal Drugs of Candidiasis: Achievements and Challenges

  2021cites this paper
• The current place of echinocandins in the treatment and prophylaxis of invasive fungal infections

  2020cites this paper
• Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases.

  2019cites this paper
• Antifungal peptides: Biosynthesis, production and applications

  2018cites this paper
• A Comparative Study of the Effects of Intravitreal Anidulafungin, Voriconazole, and Amphotericin B in an Experimental Candida Endophthalmitis Model

  2017cites this paper
• Isolation, identification and characterization of potential impurities of anidulafungin

  2017cites this paper
• Echinocandins in antifungal pharmacotherapy

  2017cites this paper
• Anidulafungin-Induced Suicidal Erythrocyte Death

  2016cites this paper
• Safety and Efficacy of Anidulafungin for Fungal Infection in Patients With Liver Dysfunction or Multiorgan Failure

  2016cites this paper
• Impact of special patient populations on the pharmacokinetics of echinocandins

  2015cites this paper
• Echinocandins--new antifungal agents.

  2014cites this paper
• An open‐label study of anidulafungin for the treatment of candidaemia/invasive candidiasis in Latin America

  2014cites this paper
• Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non‐albicans Candida species

  2014cites this paper
• QSAR MODELING OF BENZOXAZINE - 3 - ONES DERIVATIVES AGAINST CANDIDA KRUSEI

  2014cites this paper
• Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial

  2014influential citation
• A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.

  2014cites this paper
• Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial

  2013cites this paper
• Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH

  2013cites this paper
• Systematic Review and Meta-Analysis PCR Diagnosis of Invasive Candidiasis:

  2013cites this paper
• Invasive candidiasis: update on current pharmacotherapy options and future perspectives

  2013cites this paper
• Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials

  2013cites this paper
• Treatment of Candida Glabrata With Micafungin: A Case Report and Brief Review of the Literature

  2013cites this paper
• A Review on production of echinocandins by Aspergillus sp

  2013cites this paper
• Les échinocandines : mise au point

  2013cites this paper
• Utility of Antifungal Susceptibility Testing and Clinical Correlations

  2012cites this paper
• Interactions of Yeasts, Moulds, and Antifungal Agents

  2012cites this paper
• Echinocandin Antifungal Drugs in Fungal Infections

  2012cites this paper
• Non-clinical safety assessment and toxicokinetics of voriconazole and anidulafungin in the juvenile rat: a combination study design in support of a Paediatric Investigation Plan.

  2012cites this paper
• Anidulafungin

  2012cites this paper
• Anidulafungin

  2012cites this paper
• Tissue distribution of anidulafungin in neonatal rats.

  2012cites this paper
• RECENT DEVELOPMENTS IN ANTIFUNGAL AGENTS

  2012cites this paper
• Population Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Adult Patients with 1 Fungal Infections 2

  2012cites this paper
• Invasive Fungal Infections

  2012cites this paper
• Anidulafungin: when and how? The clinician’s view

  2012cites this paper
• Population Pharmacokinetic-Pharmacodynamic Analysis of Anidulafungin in Adult Patients with Fungal Infections

  2012cites this paper
• RECENT DEVELOPMENTS IN ANTIFUNGAL AGENTS Review Article

  2012cites this paper
• Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins

  2012cites this paper
• Anidulafungin, a New Echinocandin

  2012cites this paper
• 339 – Systemic Antifungal Agents

  2012cites this paper
• Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011.

  2012cites this paper
• Advances in systemic antifungal therapy.

  2012cites this paper
• Erratum to: Echinocandin antifungal drugs in fungal infections: a comparison

  2012cites this paper
• Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature

  2011cites this paper
• Anidulafungin: Review of its Role in the Treatment of Invasive Candidiasis

  2011cites this paper
• Evaluación económica de antimicóticos en pacientes no neutropénicos con candidiasis invasiva en México

  2011cites this paper
• A Comprehensive review of abdominal infections

  2011cites this paper
• Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin - review of the literature

  2011cites this paper
• Rates of Treatment Discontinuation Due to Adverse Events for Echinocandins

  2011cites this paper
• In vitro activity of echinocandins against non-Candida albicans: is echinocandin antifungal activity the same?

  2011cites this paper
• Overview of treatment options for invasive fungal infections.

  2011cites this paper
• [Echinocandins].

  2011cites this paper
• Natural Products in Drug Discovery: Impacts and Opportunities — An Assessment

  2011cites this paper
• Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections.

  2011cites this paper
• Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?

  2011cites this paper
• Anidulafungin for the treatment of invasive candidiasis.

  2011cites this paper
• Systematic Review and Meta-Analysis of the Tolerability and Hepatotoxicity of Antifungals in Empirical and Definitive Therapy for Invasive Fungal Infection

  2010cites this paper
• Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections

  2010cites this paper
• Two Drugs Better Than One? Combination Antifungal Therapy Revisited

  2010cites this paper
• [Anidulafungin: a new therapeutic option in systemic candidiasis].

  2010cites this paper
• L’anidulafungine : état de la littérature

  2010cites this paper
• Les antifongiques disponibles pour le traitement des mycoses systémiques et cutanées profondes

  2010cites this paper
• Managing Infections in Patients With Hematological Malignancies

  2010cites this paper
• Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.

  2010cites this paper
• PCR Diagnosis of Invasive Candidiasis: Systematic Review and Meta-Analysis

  2010cites this paper
• Echinocandin pharmacodynamics: review and clinical implications.

  2010cites this paper
• New antifungal agents for the treatment of candidaemia.

  2010cites this paper
• antimycotic agents: the role of echinocandins today

  2010cites this paper
• Antifungal treatment of small animal veterinary patients.

  2010cites this paper
• Novel, broad-specrum antimycotic agents: the role of echinocandins today

  2010cites this paper
• Comparison of Anidulafungin MICs Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Method (M27-A3 Document) and Etest for Candida Species Isolates

  2009cites this paper
• Pharmacology and Antifungal Properties of Anidulafungin, a New Echinocandin

  2009cites this paper
• Immediate cross-hypersensitivity between Micafungin and Caspofungin: A case report

  2009cites this paper
• pharmacotherapy of Candida Infections with echinocandins

  2009cites this paper
• Activity of Anidulafungin in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)-β-d-Glucan Levels

  2009cites this paper
• Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination

  2009cites this paper
• Amphotericin B – Based Preparations

  2009cites this paper
• Expansion of a recent class of broad-spectrum antifungal agents: the echinocandins

  2009cites this paper
• Pharmacotherapy of Micafungin: Clinical Review

  2009cites this paper
• Fungal and Parasitic Infections

  2009cites this paper
• Anidulafungin (ANID) Potency Compared to other Antifungal Agents: SENTRY Antimicrobial Surveillance Program Results for 2008 (Worldwide)

  2009cites this paper
• Chapter 4 Fungal and Parasitic Infections

  2009cites this paper
• Echinocandins for prevention and treatment of invasive fungal infections

  2009cites this paper
• Echinocandins: The Newest Class of Antifungals

  2009cites this paper
• Anidulafungin and its role in candida infections

  2009cites this paper
• A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis

  2008cites this paper
• Anidulafungin: a novel echinocandin for candida infections.

  2008cites this paper
• Early Clinical Experience with Anidulafungin at a Large Tertiary Care Medical Center

  2008cites this paper
• Chapter 53 – Antifungal and Antiviral Therapy

  2008cites this paper
• Treatment of Invasive Candidiasis in Immunocompromised Pediatric Patients

  2008cites this paper
• An evaluation of intravenous antifungal medications in patients in a paediatric hospital

  2008cites this paper
• Current Options in Antifungal Pharmacotherapy

  2008cites this paper
• Nouvelles approches thérapeutiques des infections fongiques : place des nouvelles molécules

  2008cites this paper
• [Therapeutic efficacy of anidulafungin for the treatment of oesophageal candidiasis, candidemia and invasive candidiasis].

  2008cites this paper